Antigal, Apple A.
HRN: 16-69-65 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/30/2022
CO-AMOXICLAV 625MG (TAB)
11/30/2022
12/07/2022
ORAL
625mg
Q12
S/P Completion Curettage
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes